Heron Therapeutics, Inc.
HRTX
$0.40
-$0.05-10.74%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.48% | 7.36% | 12.60% | 9.78% | 12.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.48% | 7.36% | 12.60% | 9.78% | 12.43% |
| Cost of Revenue | 5.75% | -2.81% | -5.92% | -26.49% | -39.48% |
| Gross Profit | -0.89% | 13.69% | 25.15% | 47.13% | 114.62% |
| SG&A Expenses | 6.08% | 3.17% | 11.87% | 1.70% | -9.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.97% | 1.05% | 5.10% | -10.11% | -22.74% |
| Operating Income | -192.42% | 77.98% | 119.19% | 104.28% | 94.48% |
| Income Before Tax | -297.44% | -48.71% | 51.45% | 98.07% | 90.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -297.44% | -48.71% | 51.45% | 98.07% | 90.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -297.44% | -48.71% | 51.45% | 98.07% | 90.38% |
| EBIT | -192.42% | 77.98% | 119.19% | 104.28% | 94.48% |
| EBITDA | -568.17% | 97.52% | 169.45% | 113.67% | 98.03% |
| EPS Basic | -245.12% | -30.68% | 57.91% | 98.12% | 91.67% |
| Normalized Basic EPS | -177.37% | 37.63% | 102.74% | 103.04% | 92.16% |
| EPS Diluted | -210.27% | -43.78% | 51.53% | 94.51% | 90.50% |
| Normalized Diluted EPS | -153.38% | 32.85% | 97.01% | 101.25% | 91.42% |
| Average Basic Shares Outstanding | 14.76% | 9.25% | 3.52% | 1.96% | 7.50% |
| Average Diluted Shares Outstanding | 7.15% | 16.38% | 10.65% | 9.18% | 15.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |